FDA Releases Draft Guidance for Psychedelic Drug Research
The U.S. Food and Drug Administration (FDA) has published its Draft Guidance for the research of psychedelic drugs, including psilocybin, LSD, and MDMA. This guidance outlines the regulatory requirements and unique challenges associated with studying the therapeutic potential of these substances. The FDA aims to ensure that clinical studies are designed appropriately to evaluate safety […]
FDA Releases Draft Guidance for Psychedelic Drug Research Read More »









